At a glance: In-line Double digit product salesgrowth in 2013.
Strategy Business model Our strategy describes how we will We implement our strategy through achieveour vision.
It is our structure forsuccess and drives our growth.
Our strategy is to grow our business anddeliver value to our stakeholders During 2013 we unified our business byfocusing on significant unmet ourOne Shire model has created a patientneedsin specialist areas and simple structure and focused efficient providing more innovative treatments organization that is scalable for growth.
SEE PAGE 18 SEE PAGE 18 Year on product growth $M Our four business units 2013 2012 VYVANSE 19% ELAPRASE 10% Rare Diseases LIALDA 32% MEZAVANT REPLAGAL -6% ADDERALL XR -12% Neuroscience VPRIV 12% INTUNIV 16% PENTASA 6% Gastrointestinal FIRAZYR 102% 7% FORSRENAL XAGRID 2% Internal Medicine -11% Other 14 SHIRE PLC ANNUAL REPORT 2013 WWW.
COM Governance Financial statements Other information Strategic report A DHD Hunter syndrome Ulcerative colitis $1,228m $546m $529m 2012: $1,030m 2012: $498m 2012: $400m VYVANSE product sales grew strongly Reported ELAPRASE sales growth The growth in product sales for 19% in 2013 primarily as a result of 10% was driven by an increase in LIALDA MEZAVANT 32% in price increases as well as higher the number of patients on therapy.
2013was primarily driven by higher prescription demand, due to growth Theincrease in ELAPRASE sales market share in the US, the effects inthe US ADHD market 6% and between Q3 and Q4 of 2013 was ofwhich were partially offset by VYVANSEs share of that market.
partly driven by the timing of certain highersales deductions in 2013 large orders from markets which ascompared to 2012. orderless frequently.
Fabry disease ADHD Gaucher disease $468m $375m $343m 2012: $497m 2012: $429m 2012: $307m REPLAGAL sales were down 6% ADDERALL XR product sales Reported VPRIV sales growth of compared to 2012 down 4% on a decreased 12% in 2013 as a result 12%was driven by an increase in CER basis as sales in 2013 were ofhigher sales deductions, partially thenumber of patients on therapy.
impacted by foreign exchange, pricing offset by the effect of higher stocking pressure primarily in Europe and in 2013 compared to 2012. slightly lower volumes due to the return of competition to the Fabry market.
ADHD Ulcerative colitis Hereditary Angiodema $335m $281m $235m 2012: $288m 2012: $266m 2012: $116m INTUNIV product sales were up 16% PENTASA product sales were up FIRAZYR sales growth 102% compared to 2012, driven by growth 6%as the benefit of price increases compared to 2012 was primarily inUS prescription demand up 9% was partially offset by higher sales driven by the US market, where we compared to 2012, together with deductions in 2013 as compared continue to see both good growth in priceincreases.
new patients and increased levels of were partially offset by higher sales repeat usage by existing patients.
COM ANNUAL REPORT 2013 SHIRE PLC 15
